UBS Group AG Increases Stock Holdings in Smith & Nephew SNATS, Inc. $SNN

Posted by George Bondi on May 21st, 2026

UBS Group AG grew its stake in Smith & Nephew SNATS, Inc. (NYSE:SNN – Free Report) by 12.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 165,361 shares of the medical equipment provider’s stock after purchasing an additional 18,777 shares during the period. UBS Group AG’s holdings in Smith & Nephew SNATS were worth $5,425,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Paradigm Asset Management Co. LLC acquired a new stake in shares of Smith & Nephew SNATS during the third quarter worth $1,502,000. Todd Asset Management LLC purchased a new position in Smith & Nephew SNATS during the 3rd quarter worth $26,319,000. Citigroup Inc. raised its position in Smith & Nephew SNATS by 44.8% during the 3rd quarter. Citigroup Inc. now owns 486,661 shares of the medical equipment provider’s stock worth $17,661,000 after buying an additional 150,517 shares during the last quarter. Factory Mutual Insurance Co. acquired a new stake in shares of Smith & Nephew SNATS in the 3rd quarter worth $1,007,000. Finally, Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Smith & Nephew SNATS in the 3rd quarter worth $16,501,000. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Analyst Upgrades and Downgrades

SNN has been the topic of a number of recent analyst reports. Wall Street Zen lowered shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Monday, April 20th. Canaccord Genuity Group lowered their price objective on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating on the stock in a report on Monday, May 11th. Finally, Sanford C. Bernstein set a $31.85 target price on Smith & Nephew SNATS in a research report on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $30.93.

View Our Latest Stock Report on SNN

Smith & Nephew SNATS Stock Up 0.4%

Shares of NYSE SNN opened at $30.98 on Thursday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.25 and a current ratio of 2.57. Smith & Nephew SNATS, Inc. has a one year low of $28.23 and a one year high of $38.79. The company’s fifty day moving average is $32.01 and its two-hundred day moving average is $33.24.

Smith & Nephew SNATS (NYSE:SNN – Get Free Report) last announced its quarterly earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share (EPS) for the quarter. The company had revenue of $1.60 billion during the quarter. As a group, equities analysts forecast that Smith & Nephew SNATS, Inc. will post 2.25 EPS for the current year.

Smith & Nephew SNATS Announces Dividend

The business also recently announced a dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Friday, March 27th will be issued a $0.482 dividend. The ex-dividend date of this dividend is Friday, March 27th. This represents a yield of 304.0%.

Smith & Nephew SNATS Profile

(Free Report)

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.